BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 18406001)

  • 1. Gestational diabetes has no additional effect on plasma thrombin-activatable fibrinolysis inhibitor antigen levels beyond pregnancy.
    Akinci B; Demir T; Saygili S; Yener S; Alacacioglu I; Saygili F; Bayraktar F; Yesil S
    Diabetes Res Clin Pract; 2008 Jul; 81(1):93-6. PubMed ID: 18406001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levels of thrombin activatable fibrinolysis inhibitor in gestational diabetes mellitus.
    Gumus II; Kargili A; Karakurt F; Kasapoglu B; Derbent A; Kaygusuz I; Koca C; Sevgili S
    Gynecol Endocrinol; 2013 Apr; 29(4):327-30. PubMed ID: 23327722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma thrombin-activatable fibrinolysis inhibitor levels are not associated with glucose intolerance and subclinical atherosclerosis in women with previous gestational diabetes.
    Akinci B; Celtik A; Yener S; Genc S; Tunali S; Yuksel F; Ozcan MA; Secil M; Yesil S
    Clin Appl Thromb Hemost; 2011; 17(6):E224-30. PubMed ID: 21406417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients.
    Kitagawa N; Yano Y; Gabazza EC; Bruno NE; Araki R; Matsumoto K; Katsuki A; Hori Y; Nakatani K; Taguchi O; Sumida Y; Suzuki K; Adachi Y
    Diabetes Res Clin Pract; 2006 Aug; 73(2):150-7. PubMed ID: 16458385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.
    Ermantas N; Guldiken S; Demir M; Tugrul A
    Clin Appl Thromb Hemost; 2010 Oct; 16(5):568-73. PubMed ID: 19959491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in activity of plasma thrombin activatable fibrinolysis inhibitor in pregnancy.
    Watanabe T; Minakami H; Sakata Y; Matsubara S; Sato I; Suzuki M
    Gynecol Obstet Invest; 2004; 58(1):19-21. PubMed ID: 15004439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TAFI activity and antigen plasma levels are not increased in acute coronary artery disease patients admitted to a coronary care unit.
    Paola Cellai A; Antonucci E; Alessandrello Liotta A; Fedi S; Marcucci R; Falciani M; Giglioli C; Abbate R; Prisco D
    Thromb Res; 2006; 118(4):495-500. PubMed ID: 16318869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease.
    Koutroubakis IE; Sfiridaki A; Tsiolakidou G; Coucoutsi C; Theodoropoulou A; Kouroumalis EA
    Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):912-6. PubMed ID: 18794606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship among TAFI, t-PA, PAI-1 and F1 + 2 in type 2 diabetic patients with normoalbuminuria and microalbuminuria.
    Chudý P; Kotuličová D; Staško J; Kubisz P
    Blood Coagul Fibrinolysis; 2011 Sep; 22(6):493-8. PubMed ID: 21519232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with polycystic ovary syndrome.
    Oral B; Mermi B; Dilek M; Alanoğlu G; Sütçü R
    Gynecol Endocrinol; 2009 Feb; 25(2):110-6. PubMed ID: 19253106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrinolytic dysfunction in insulin-resistant women with previous gestational diabetes.
    Farhan S; Winzer C; Tura A; Quehenberger P; Bieglmaier C; Wagner OF; Huber K; Waldhäusl W; Pacini G; Kautzky-Willer A
    Eur J Clin Invest; 2006 May; 36(5):345-52. PubMed ID: 16634839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma levels of thrombin activatable fibrinolysis inhibitor in normal and preeclamptic pregnant women.
    Alacacioğlu I; Ozcan MA; Alacacioğlu A; Polat M; Yüksel F; Demirkan F; Pişkin O; Ozgenç Y; Ozsan HG; Undar B
    Thromb Res; 2004; 114(3):155-9. PubMed ID: 15342211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence that fibrinolytic changes in paediatric obesity translate into a hypofibrinolytic state: relative contribution of TAFI and PAI-1.
    Semeraro F; Giordano P; Faienza MF; Cavallo L; Semeraro N; Colucci M
    Thromb Haemost; 2012 Aug; 108(2):311-7. PubMed ID: 22740053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.
    Yener S; Comlekci A; Akinci B; Demir T; Yuksel F; Ozcan MA; Bayraktar F; Yesil S
    Med Princ Pract; 2009; 18(4):266-71. PubMed ID: 19494532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coagulation and fibrinolysis parameters in normal pregnancy and in gestational diabetes.
    Bellart J; Gilabert R; Fontcuberta J; Carreras E; Miralles RM; Cabero L
    Am J Perinatol; 1998 Aug; 15(8):479-86. PubMed ID: 9788646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrinolytic dysfunction after gestation is associated to components of insulin resistance and early type 2 diabetes in latino women with previous gestational diabetes.
    Morimitsu LK; Fusaro AS; Sanchez VH; Hagemann CC; Bertini AM; Dib SA
    Diabetes Res Clin Pract; 2007 Dec; 78(3):340-8. PubMed ID: 17544539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis.
    Colucci M; Binetti BM; Branca MG; Clerici C; Morelli A; Semeraro N; Gresele P
    Hepatology; 2003 Jul; 38(1):230-7. PubMed ID: 12830006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of fibrinolytic and antifibrinolytic activities in the pathophysiology of HELLP syndrome.
    Guven S; Sonmez M; Karahan SC
    Hypertens Pregnancy; 2011; 30(3):275-86. PubMed ID: 19943771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of short-term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI-1.
    Ozeren M; Karahan SC; Ozgur M; Eminagaoglu S; Unsal M; Baytan S; Bozkaya H
    Acta Obstet Gynecol Scand; 2005 Oct; 84(10):987-91. PubMed ID: 16167916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombin activatable fibrinolysis inhibitor (TAFI) in human amniotic fluid. A preliminary study.
    Uszyński W; Uszyński M; Zekanowska E
    Thromb Res; 2007; 119(2):241-5. PubMed ID: 16540154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.